ANDA 75702, held by Bausch & Lomb. Cromolyn Sodium.
As of Nov 19, 2026, ANDA 75702 (Cromolyn Sodium), held by Bausch & Lomb, was first approved by FDA on Jul 3, 2001, with 0 approved supplements and 0 published complete response letters.
Uses to prevent and relieve nasal symptoms of hay fever and other nasal allergies:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 3, 2001 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium5.2MG/SPRAY · spray, metered;nasal | Cromolyn Sodium | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters